HFMD

SINOVAC Varicella Vaccine Prequalified by WHO

Retrieved on: 
Friday, November 4, 2022
Health, Infectious Diseases, COVID-19, Clinical Trials, Pharmaceutical, Biotechnology, Company, Mumps, Polio, III, World, Influenza A virus subtype H1N1, World Health Organization, WHO, Foot-and-mouth disease virus, Hepatitis A, Vaccine, COVID-19, H5N1, CEO, National TB Elimination Program (India), Chickenpox, Seroconversion, HFMD, Oka, NASDAQ, Infection, R, Streptococcus, EV71, Program, Sinovac Biotech

This marks the first WHO prequalified Chinese varicella vaccine and the fourth SINOVAC vaccine to receive WHO approval.

Key Points: 
  • This marks the first WHO prequalified Chinese varicella vaccine and the fourth SINOVAC vaccine to receive WHO approval.
  • Mr. Weidong Yin, Chairman, President and CEO of Sinovac, commented, Now that SINOVAC has received WHO prequalification for our varicella vaccine, we can provide a new weapon for prevention and control of infectious diseases globally.
  • Previously, three other vaccines by SINOVAC were also approved by WHO in various uses and conditions, including Healive (the hepatitis A vaccine), CoronaVac (the COVID-19 vaccine) and the Sabin-strain inactivated polio vaccine.
  • In 2022, SINOVACs Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO.

SINOVAC to Showcase Products at CPHI Frankfurt

Retrieved on: 
Friday, October 28, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Infectious Diseases, R, Chickenpox, Company, Influenza A virus subtype H1N1, Mumps, NASDAQ, Polio, H5N1, Vaccine, Pyaar Tune Kya Kiya (TV series), Foot-and-mouth disease virus, Booth, EV71, Streptococcus, Program, COVID-19, Infection, HFMD, Hepatitis A, WHO, Sinovac Biotech, Fine chemical

Sinovac Biotech Ltd. (SINOVAC or the Company) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that the Company will participate in CPHI Frankfurt, one of the worlds largest pharmaceutical exhibitions, from 1st to 3rd of November, in Frankfurt, Germany.

Key Points: 
  • Sinovac Biotech Ltd. (SINOVAC or the Company) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that the Company will participate in CPHI Frankfurt, one of the worlds largest pharmaceutical exhibitions, from 1st to 3rd of November, in Frankfurt, Germany.
  • At Booth#41G20, the first floor of Hall 4, Messe Frankfurt, SINOVAC will greet all visitors of CPHI and present its comprehensive portfolio.
  • Helen Yang, Chief Business Officer of SINOVAC said, SINOVAC is an old friend of CPHI, and we are happy to finally return to CPHIs in-person event for the first time since the outbreak of the COVID-19 pandemic globally.
  • SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities.

SINOVAC Approved to Initiate Clinical Trial for Its Omicron Containing COVID-19 Vaccine in Chile

Retrieved on: 
Tuesday, September 6, 2022
Research, Infectious Diseases, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Valence (chemistry), COVID-19, CEO, Safety, Program, Influenza A virus subtype H1N1, WHO, NASDAQ, Vaccine, Streptococcus, R, Infection, H5N1, Instituto Butantan, HFMD, Polio, Chickenpox, Hepatitis A, Mumps, ISP, Company, Foot-and-mouth disease virus, RNA transfection, Clinical trial, Delta, EV71, Sinovac Biotech, Omicron

In this phase II randomized, double-blind, multicenter clinical trial, 826 fully vaccinated adults will be recruited.

Key Points: 
  • In this phase II randomized, double-blind, multicenter clinical trial, 826 fully vaccinated adults will be recruited.
  • Mr. Weidong Yin, the Chairman, President, and CEO of SINOVAC said, SINOVAC has made great progress collaborating with global partners in the development and manufacturing of the COVID-19 vaccine.
  • Its COVID-19 vaccine, CoronaVac, has been approved for use in more than 60 countries and regions worldwide.
  • SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities.

SINOVAC COVID-19 Vaccine Approved for Use in Children Above 6 months of Age in Hong Kong

Retrieved on: 
Wednesday, August 3, 2022
Biotechnology, Pharmaceutical, General Health, Health, COVID-19, Children, Infectious Diseases, Consumer, NASDAQ, Vaccine, Safety, Foot-and-mouth disease virus, Minor, Department, R, Program, Center, Health Bureau, H5N1, WHO, Scientific Committee on Antarctic Research, Infection, HFMD, Sinovac Biotech, Mumps, III, Scientific Committee on Emerging and Newly Identified Health Risks, Polio, Chickenpox, Hepatitis A, COVID-19, CoronaVac, Company, EV71, Carrie Lam as Chief Executive of Hong Kong, Vaccination, Streptococcus, COVID-19 vaccine, Ageing, Zoonosis, Influenza A virus subtype H1N1, Government

The vaccination schedule for this age group follows the same vaccination schedule of older children.

Key Points: 
  • The vaccination schedule for this age group follows the same vaccination schedule of older children.
  • SINOVAC initiated its COVID-19 vaccine (CoronaVac) phase III clinical studies among children aged 6 months to 17 years since 2021.
  • Preliminary results show the vaccine has a good safety and immunogenicity profile, with no severe adverse reaction reported 6 months after two doses of vaccination among children aged 6 months to 35 months.
  • SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities.

SINOVAC Initiates Clinical Trial for Its Quadrivalent Influenza Vaccine in Chile

Retrieved on: 
Tuesday, July 19, 2022
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Infectious Diseases, Clinical Trials, Influenza A virus subtype H1N1, III, Chickenpox, Volunteering, Infection, WHO, Safety, Republic, Polio, Foot-and-mouth disease virus, Program, EV71, PI, NASDAQ, Sinovac Biotech, COVID-19, Company, Hepatitis A, Ageing, Mumps, Streptococcus, H5N1, Vaccine, Clinical trial, HFMD, R, Coro de la Pontificia Universidad Católica de Puerto Rico

This clinical trial aims to evaluate the immunogenicity and safety of the quadrivalent influenza vaccine among individuals aged 3 and above.

Key Points: 
  • This clinical trial aims to evaluate the immunogenicity and safety of the quadrivalent influenza vaccine among individuals aged 3 and above.
  • In total, there will be 1,600 volunteers recruited, half of whom will receive 1 dose of SINOVACs inactivated quadrivalent influenza vaccine, and the other half will receive a different quadrivalent influenza vaccine commercially available in Chile.
  • Children aged between 3 and 8 of both groups who havent received any influenza vaccine will receive 2 doses of influenza vaccine.
  • The upcoming clinical trial in Chile will provide further evidence on the efficacy and safety of SINOVACs quadrivalent influenza vaccine.

SINOVAC COVID-19 Vaccine Is Authorized for Emergency Use in Kids Aged 3-5 In Brazil

Retrieved on: 
Thursday, July 14, 2022
COVID-19, Research, Infectious Diseases, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, COVID-19, Influenza A virus subtype H1N1, Program, Pulmonology, Vaccine, H5N1, Infection, HFMD, SBP, WHO, Vaccination, Company, Hepatitis A, R, Mumps, Foot-and-mouth disease virus, Ageing, Brazilian Association of Investigative Journalism, Minor, SBI, Chickenpox, Instituto Butantan, Sinovac Biotech, Research, Association, CoronaVac, EV71, Streptococcus, To Brazil!, NASDAQ, Polio, Pharmaceutical industry, Brazilian Health Regulatory Agency, COVID-19, Research, Infectious Diseases, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science

This authorization was given under comprehensive evaluations based on analysis results from all available data on the vaccine and its use in children.

Key Points: 
  • This authorization was given under comprehensive evaluations based on analysis results from all available data on the vaccine and its use in children.
  • To assist Anvisa in evaluating the vaccine, the experts from the above institutions had access to technical materials and research data on the vaccine.
  • CoronaVac has been authorized for emergency use for adults in Brazil since January 17, 2021.
  • SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities.

SINOVAC COVID-19 Vaccine Is Conditionally Registered In South Africa

Retrieved on: 
Saturday, June 25, 2022
Biotechnology, Pharmaceutical, Health, COVID-19, Influenza A virus subtype H1N1, Research, SAHPRA, Chinese government award for outstanding self finance students abroad, Polio, COVID-19, South African Health Products Regulatory Authority, Company, Hepatitis A, Hepatitis, Ageing, Infection, H5N1, Streptococcus, Sinovac Biotech, Risk management, Foot-and-mouth disease virus, NASDAQ, Vaccine, HFMD, Chickenpox, Safety, Mumps, EV71, WHO, Pharmaceutical industry

All the evidence suggested that the SINOVAC COVID-19 vaccine was safe and effective.

Key Points: 
  • All the evidence suggested that the SINOVAC COVID-19 vaccine was safe and effective.
  • SINOVAC COVID-19 vaccine has been available in more than 60 countries, with a total supply of almost 2.9 billion doses.
  • Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the research, development, manufacturing, and commercialization of vaccines that protect against human infectious diseases.
  • SINOVAC has been continually dedicating itself to new vaccine research and development, with more combination vaccine products in the pipeline, and constantly exploring opportunities in the international market.

Legend Capital's Portfolio Company Recbio Lists on HKEX Successfully

Retrieved on: 
Thursday, April 7, 2022
People, Shingles, Innovation, HFMD, Investment, III, HPV, Protein engineering, Board, Adult, Vaccine, Research, General manager, Investor, Philosophy, WuXi Biologics, Industry, Technology, RNA transfection, Cervical cancer, COVID-19, Wuxi, COVID-19 vaccine, Tuberculosis, R, Founder, Patient, Hong Kong Stock Exchange, Property management

HONG KONG, Apr 7, 2022 - (ACN Newswire) - On 31 March 2022, Legend Capital's portfolio company Jiangsu Recbio Technology Co., Ltd. ("Recbio", stock code: 2179.HK), a leading novel vaccines company, went public on the Hong Kong Stock Exchange.

Key Points: 
  • HONG KONG, Apr 7, 2022 - (ACN Newswire) - On 31 March 2022, Legend Capital's portfolio company Jiangsu Recbio Technology Co., Ltd. ("Recbio", stock code: 2179.HK), a leading novel vaccines company, went public on the Hong Kong Stock Exchange.
  • Recbio is a novel vaccine company driven by independent novel adjuvant technology.
  • As the major institutional investor to Recbio, Legend Capital provides Recbio with multi-faceted support involving corporate governance, business strategy, technical route, R&D resources, management improvement and financial support.
  • Hank Zhou, the Co-Chief Investment Officer of Legend Capital, said: "Congratulations to Recbio and its team led by founder Dr. Liu Yong.

Official Listing of Recbio on HKEX, Vaccine Innovation and Iteration Accelerated by Novel Adjuvant Technology

Retrieved on: 
Friday, April 1, 2022
Company, Cornerstone, CAGR, Benchmarking, Shingles, HFMD, World Health Organization, Protein engineering, III, HPV, Transport, Public health, Board, Adult, Vaccine, EUA, Temasek, Yangtze River Pharmaceutical Group, Research, Delta, Environment, Cervical cancer, World, General manager, GFA, Frost & Sullivan, Global, Omicron, Technology, Safety, TB, RNA transfection, Depression, COVID-19, Intellectual property, Pharmaceutical industry, Frost, COVID-19 vaccine, Tuberculosis, GMP, IPO, FDA, Development, Founder, R, Temperature, Hong Kong Stock Exchange, Recovered-memory therapy

Regarding the development of the vaccine industry, the "Plan" also states that research and development of novel vaccines (such as novel adjuvants for vaccines and mRNA vaccines) and building of industrialization capability shall be accelerated.

Key Points: 
  • Regarding the development of the vaccine industry, the "Plan" also states that research and development of novel vaccines (such as novel adjuvants for vaccines and mRNA vaccines) and building of industrialization capability shall be accelerated.
  • Currently, Recbio has formed a full coverage of bivalent, quadrivalent and 9-valent vaccines and novel adjuvant upgrades in the field of HPV vaccines.
  • The novel adjuvant which benchmarking AS01 is adopted in REC610 of the Company, significantly improving vaccine immunogenicity, hoping to achieve domestic substitution quickly.
  • Founded in 2012, Recbio is an innovative vaccine company with independent research and development technology as its core driving force.

Recbio Announces Proposed Listing on the Main Board of the Hong Kong Stock Exchange

Retrieved on: 
Sunday, March 20, 2022
BLA, CAGR, HFMD, Adult, Vaccine, EUA, HK, NMPA, Healthcare industry, Technology, TB, Stock exchange, Pi, Solution, GMP, Science, Frost, Disease, Hong Kong Stock Exchange, Post-exposure prophylaxis, Sequoia Capital, Population, Cros, Investor, GFA, Global, Industry, Development, Shingles, WHO, III, Clinical trial, Growth, Motherboard, Core product, Board, Temasek, IPD, S. D. Warren Co. v. Maine Board of Environmental Protection, Data analysis, IND Queens Boulevard Line, Cervical cancer, COVID-19 vaccine, FDA, Recovered-memory therapy, Company, HPV, Compliance, AS04, Research, Antigen, General manager, Frost & Sullivan, Safety, Disability-adjusted life year, COVID-19, CLSA, R, Tuberculosis, Property management, Pharmaceutical industry

Recbio will open for Hong Kong Public Offering in Hong Kong at 9:00 a.m., 21 March 2022 (Monday), and close at 12:00 noon, 24 March 2022 (Thursday).

Key Points: 
  • Recbio will open for Hong Kong Public Offering in Hong Kong at 9:00 a.m., 21 March 2022 (Monday), and close at 12:00 noon, 24 March 2022 (Thursday).
  • Dealings in H Shares of Recbio on the Main Board of the Hong Kong Stock Exchange is expected to commence on 31 March 2022 (Thursday).
  • -- China Industrial Securities International Capital Limited, Haitong International Securities Company Limited, GF Securities (Hong Kong) Brokerage Limited, Essence International Securities (Hong Kong) Limited and Valuable Capital Limited (in relation to the Hong Kong Public Offering only) are the Joint Bookrunners and Joint Lead Managers.
  • Recbio is the vaccine company with a high-value vaccine portfolio driven by in-house developed technologies.